/

AFMDQ

Affimed N.V.Closed

0.0003000.00 0.00%USD

OTC Markets OTCPK · as of Oct 12, 16:00 ET · 15m delay

Open

0.000100

Prev close

0.000300

Day range

0.0001000.000100

52-week range

0.0000100.0500

Volume

2.60K0.35×

Mkt cap

4.92K

P/E ttm

—

Fwd P/E

—

EPS ttm

-7.47

Div yield

0.00%

Earnings

—

From 52w high

−99.40%

Price Chart

Yahoo Finance · delayed

AFMDQOct 12, 2026O 0.0003H 0.0003L 0.0003C 0.00030.0000 (0.00%)Vol 12.53K

SMA 500.0001
SMA 2000.0001

1Y change +200.00% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AFMDQ Affimed N.V. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +50.00%
1 month: +200.00%
3 months: +200.00%
6 months: +200.00%
Year to date: +200.00%
1 year: +200.00%

Valuation & ownership

Market cap: 4.92K
Enterprise value: −11.21M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 0.00
Price / sales (ttm): 0.00
EV / EBITDA: 0.18
EPS (ttm): -7.47
EPS (forward): —
Beta (5y monthly): 0.28
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 16.39M
Float: 15.48M
Short % of float: 3.75%
Short ratio (days): 4.60
Held by insiders: 0.00%
Held by institutions: 0.00%
Avg volume (3m): 7.46K
50-day average: 0.000124
200-day average: 0.000145
52-week change: +200.00%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): overbought 98.9
vs 50-day SMA: +141.94%
vs 200-day SMA: +111.86%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.46%
Realised vol (20d, ann.): 278.4%
From 52-week high: −99.40%
From 52-week low: +2,900.00%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 5.64M
Revenue growth (yoy): −91.60%
Earnings growth (yoy): —
Gross margin: 100.00%
Operating margin: -8709.15%
Profit margin: 0.00%

DES

About Affimed N.V.

Yahoo Finance profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Sector: Healthcare
Industry: Biotechnology
Employees: 76
Headquarters: Mannheim, Germany
Website: affimed.com
Officers: Dr. Wolfgang Fischer Ph.D. MD, COO, Chief Strategy Officer & Member of Management Board

SEAS

Seasonality · AFMDQ

2014–2026 · monthly returns

Strongest month Jan +259.36%Weakest month Dec −13.55%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.0	0.0	100.0	-50.0	0.0	0.0	0.0	0.0	0.0	200.0			+200.0%
2025	-15.1	2.0	-29.8	37.6	-97.0	155.1	-73.6	-99.5	0.0	0.0	0.0	0.0	−100.0%
2024	781.6	9.3	-12.0	0.9	-18.7	25.3	-7.0	-16.6	-20.6	-3.9	-12.1	-58.1	+90.4%
2023	-89.6	-29.5	-18.0	20.7	-2.3	-32.0	-1.4	-7.8	-12.2	-17.3	13.9	38.9	−95.0%
2022	639.1	8.1	-0.9	-14.0	-17.6	-10.6	2.2	-7.4	-21.4	-14.6	21.6	-42.1	+124.6%
2021	-1.5	-1.0	39.5	35.1	-17.0	-4.2	-21.8	5.9	-12.2	10.0	0.3	-19.1	−5.2%
2020	-4.4	-9.9	-33.1	38.6	50.2	40.3	-23.5	-2.3	-1.7	-6.8	69.0	9.0	+112.4%
2019	10.3	2.3	19.7	-21.4	-7.9	-5.6	4.5	-7.3	5.8	0.0	-12.2	6.2	−11.9%
2018	-89.8	60.4	-12.9	5.4	10.3	-23.3	9.1	202.8	-20.2	-27.6	42.2	-30.6	−76.1%
2017	900.0	11.1	15.0	-2.2	-2.2	-6.8	7.3	-9.7	13.2	-6.7	-7.1	-33.3	+622.2%
2016	-95.3	-3.9	17.2	8.3	-12.1	-30.3	5.6	-4.2	10.8	-26.3	-2.4	-10.0	−97.5%
2015	817.7	8.4	2.1	25.4	32.0	29.1	21.8	-38.6	-38.8	2.8	17.7	-4.6	+1048.4%
2014										-25.1	62.1	-19.0	−1.6%

AFMDQ

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AFMDQ

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Affimed N.V.

Seasonality · AFMDQ

Insider Activity · AFMDQ

Congress Trades · AFMDQ

Investors Holding AFMDQ

Investors Holding AFMDQ

Congress Trades · AFMDQ

Insider Activity · AFMDQ

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Affimed N.V.

Earnings & Dividends

News

Seasonality · AFMDQ